Investing in politics

While most biotechnology companies are more concerned with equity funding than campaign funding, a few biotech players have bought into Washington.Sanford Robertson and Mark Simon of Robertson, Stephens & Co. helped raise large sums for the Clinton-Gore campaign.

A perusal of Federal Election Commission records reveals names of other important biotech executives and investors who